Market Place
Sourcing Support
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
27 Nov 2019 //
RAPS
Catalent, BeiGene Enter Long-Term Supply Agreement
21 Nov 2019 //
CONTRACT PHARMA
BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica
16 Nov 2019 //
FIERCE PHARMA
China`s BeiGene scores FDA approval but can they carve up J&J`s blockbuster
14 Nov 2019 //
ENDPTS
BeiGene hits back at short seller`s accusations of 60% sales inflation
10 Sep 2019 //
FIERCE PHARMA
FDA Grants Priority Review to Zanubrutinib as Treatment for Mantle Cell Lymphoma
23 Aug 2019 //
LYMPHOMANEWSTODAY
BeiGene & Mustang nail down special FDA status for top drugs
23 Aug 2019 //
ENDPTS
BeiGene touts `encouraging` response rates
18 Jun 2019 //
ENDPTS
What`s BeiGene`s plan for Celgene-partnered PD-1?
31 May 2019 //
FIERCE PHARMA
MEI Pharma, BeiGene to Evaluate ME-401 + Zanubrutinib in B-Cell Malignancies
11 Oct 2018 //
PR NEWSWIRE
BeiGene eyes monster $800M-plus Hong Kong IPO
30 Jul 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.